Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE.
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin, thereby preventing fibrin formation and thrombus propagation.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
For treatment of venous thromboembolism: Initial IV bolus of 80 units/kg, then continuous IV infusion at 18 units/kg/hour. For prophylaxis: Subcutaneous injection of 5000 units every 8-12 hours. Heparin sodium 12,500 units/250 mL (50 units/mL) is typically used for continuous IV infusion.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Terminal elimination half-life is dose-dependent: for bolus doses of 100, 400, and 800 U/kg, half-lives are approximately 1, 2.5, and 5 hours, respectively. In severe renal impairment, half-life may be prolonged.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Renal (primarily via reticuloendothelial system depolymerization; elimination of metabolites in urine; minimal unchanged drug excreted renally). Approximately 50% of a dose is eliminated renally as metabolites.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte